Long-term safety study of WVE-N531 for Duchenne muscular dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This trial is for people who have already taken WVE-N531 in an earlier study. It continues to check the medicine's safety and effects over a longer period.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in a previous study of WVE-N531.
- You should not have had serious side effects from WVE-N531 in the past.
- Your general health should not have gotten worse since your last dose or when you left the earlier study.
- If there is a gap of more than 31 days between your last dose in the earlier study and starting this one, the doctor and study team need to discuss it first.
- You cannot use any recreational drugs (including prescribed marijuana) within 2 months before starting this study, and you must agree not to use them during the study. Alcohol and nicotine are okay.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests WVE-N531 in people with Duchenne muscular dystrophy (DMD) whose genetics specifically match an “exon 53” change. It may help by targeting the muscle disease process, and it includes procedures like muscle biopsies and regular heart/lung checks.
This trial looks at how safely givinostat works over a longer time in people with Duchenne muscular dystrophy (DMD). It mainly checks long-term side effects and tolerability, especially in a specific subgroup of muscle fat levels.
This study watches boys with Duchenne muscular dystrophy who are already taking Agamree (vamorolone) to see how safe it is over a long period. It helps doctors understand the medicine's effects over time.
This study follows boys with Duchenne muscular dystrophy over time to better understand how the condition changes and how standard treatments affect health and function. It does not appear to test a new medicine, but it may help doctors plan better future care and studies.
This study evaluates how safe and effective ELEVIDYS (a gene therapy) is when used in real-world clinical practice for boys with Duchenne muscular dystrophy. The trial includes two groups: boys starting ELEVIDYS for the first time, and boys who have already received it commercially.
This study checks how people with Duchenne muscular dystrophy are doing long-term after receiving delandistrogene moxeparvovec (SRP-9001) in an earlier trial. It helps researchers understand the long-term safety and effects of that treatment.
Hear when a new Duchenne Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.